



Continuation of Substance of Interview including description of the general nature of what was discussed: Mr. Baude agreed to an Examiner's amendment to change the last compound entry of amended claim 61 to (2S,3R,6S)-2,6-dimethyl-4-[4-(pyridin-4-ylmethoxy)-benzenesulfonyl]-morpholine-3-carboxylic acid hydroxyamide to reflect the compound on p. 44 of the specification..